Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04855656 · ClinicalTrials.gov registry record · Phase 1

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Debiopharm International.

Recruiting
Registry status
Phase 1
Development phase
464
Enrollment target
20
Study locations

NCT04855656 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Debiopharm International. The registered enrollment target is 464 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (144% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04855656, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Debiopharm International.

RECRUITING
Registry status
Phase 1
Development phase
464 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG Lunresertib
  • DRUG RP-3500
  • DRUG Debio0123

Study Locations (20)

New York

  • #1032, Northwell Health Cancer Institute - New Hyde Park
  • #1008, Columbia University - New York
  • #1004, Memorial Sloan Kettering Cancer Institute - New York

California

  • # 1019, UCLA, Westwood Cancer Center - Los Angeles
  • #1025, University of California San Francisco - San Francisco

Rhode Island

  • #1007, Rhode Island Hospital - Providence
  • #1030, Women & Infants Hospital of Rhode Island - Providence

Ontario

  • #2002, The Hospital for Sick Children - Toronto
  • #2001, Princess Margaret Cancer Centre - Toronto

Connecticut

  • #1012, Yale - New Haven

Florida

  • #1017, Mayo Clinic - Jacksonville

Massachusetts

  • #1002, Dana Farber Cancer Institute - Boston

Michigan

  • #1023, START Midwest - Grand Rapids

Trial Details

FieldValue
Enrollment Target 464 participants
Start Date 2021-04-30
Est. Completion 2028-06
Phase Phase 1

Sponsor

Debiopharm International

30 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04855656

The ClinicalTrials.gov registry entry for NCT04855656 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (144% higher). The listed sponsor is Debiopharm International, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Lunresertib is the first listed.

NCT04855656 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, California, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT04855656 about?

NCT04855656 is a clinical study titled "Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors". The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

What is the current status of trial NCT04855656?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 464 participants. The study started on 2021-04-30. Estimated completion is 2028-06.

What conditions does trial NCT04855656 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT04855656?

The interventions under investigation include: Lunresertib (DRUG), RP-3500 (DRUG), Debio0123 (DRUG).

Who is sponsoring clinical trial NCT04855656?

This trial is sponsored by Debiopharm International, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04855656 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.